⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155774 | 1.00 | — | — | |
| SCHEMBL805219 | 1.00 | — | — | |
| SCHEMBL9343006 | 0.97 | SMN1; SMN2 (0.38) | — | |
| Hydrochloric Acid SCHEMBL3290648 | 0.97 | — | — | |
| SCHEMBL28263469 | 0.97 | — | — | |
| SCHEMBL8829580 | 0.97 | — | — | |
| Rubidium SCHEMBL9635582 | 0.97 | — | — | |
| Ethyl Chloride SCHEMBL27650306 | 0.93 | SMN1; SMN2 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL21492760 | 0.87 | POLB (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL21492763 | 0.87 | POLB (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466069-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-11-27 | — | — | EP | claimed |
| CN-117858700-A | Controlled release local injection composition containing cyclic peptide and preparation method thereof | 东方生物股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-03-14 | — | — | US | claimed |
| WO-2023139187-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | claimed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | claimed |
| CN-113651946-B | Epoxy resin curing agent and preparation method and application thereof | 万华化学集团股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-113651946-A | Epoxy resin curing agent and preparation method and application thereof | 万华化学集团股份有限公司 | 2021-11-16 | — | — | CN | claimed |
| CN-103985567-B | Supercapacitor battery | 宋大余 | 2017-05-10 | — | — | CN | claimed |
| US-8980843-B2 | Leptin agonist and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-17 | — | — | US | claimed |
| CN-103456981-A | Manufacturing method of organic lithium-containing polymer solid electrolyte film | SONG DAYU | 2013-12-18 | — | — | CN | claimed |
| US-20030211979-A1 | FAP-activated anti-tumor compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| WO-2003064454-A1 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-08-07 | — | — | WO | claimed |
| EP-1333033-A1 | FAP-activated anti-tumor compounds | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| US-5942365-A | CHARGE ADJUVANT OF ALUMINUM SALT OF AN ACID; SMEARING, LOSS OF RESOLUTION AND LOSS OF DENSITY ELIMINATED OR MINIMIZED | XEROX CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0581075-B1 | Process for preparation of lithium N-methylaminobutyrate | IDEMITSU PETROCHEMICAL CO (JP) | 1996-10-09 | — | — | EP | claimed |
| EP-0253413-B1 | NEW ANTIBIOTICS CALLED \"MUREIDOMYCINS A, B, C AND D\" A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1993-10-13 | — | — | EP | claimed |
| EP-0317292-B1 | NEW ANTIBIOTICS OF THE MUREIDOMYCIN GROUP, THEIR PREPARATION, AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1993-04-07 | — | — | EP | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0317292-A2 | New antibiotics of the mureidomycin group, their preparation, and their therapeutic use | Sankyo Company Limited (JP) | 1989-05-24 | — | — | EP | claimed |